Get the Daily Brief
Latest Biotech News
Regulatory action: new therapy approvals and advisory review
The FDA approved Takeda’s orexin receptor 2 agonist Orzeyful (oveporexton) for adults with narcolepsy type 1, marking the first therapy in the orexin-targeting approach in the US. Takeda said two...
Obesity market: injectable dominance persists as oral options launch
A Spherix Global Insights survey of 185 US healthcare specialists found Eli Lilly’s injectable Zepbound remains the top choice among currently available GLP-1 options. Respondents reported 80%...
Oncology pipeline: fast-track designations expand accelerated development
The FDA granted fast track designations for multiple oncology programs in July 2026, signaling continued regulatory focus on faster development pathways for difficult-to-treat cancers. SOTIO...
Cancer diagnostics: MRD study pipeline ramps at Natera
Natera said it is preparing to accelerate prospective readouts to better establish the clinical utility of its Signatera MRD platform. On an earnings call alongside rising Q2 revenue, the company...
Biopharma finance: major IPO fundraising for pain and cardiology
Two new biotechs broke through IPO expectations, underscoring investor appetite for late-breaking pipeline themes. BlossomHill Therapeutics and Latigo Biotherapeutics each raised more than their...
Ophthalmology deal: Tarsus buys Alkeus for late-stage Stargardt therapy
Tarsus agreed to acquire Alkeus Pharmaceuticals for up to $800 million, gaining ownership of ALK-001 (gildeuretinol), a once-daily oral therapy in Phase 3 for Stargardt disease. The deal expands...
Antimicrobial policy and market: US senators weigh AMR and biotech leadership
A bipartisan Senate hearing focused on maintaining US biotech leadership while addressing antimicrobial resistance, with lawmakers and witnesses citing AMR’s clinical and economic toll....
Clinical research update: robotic cataract surgery integrates into routine workflow
Forsight Robotics reported first-in-human data indicating its Jasper robotic platform can be integrated into routine cataract surgery without switching to manual procedures. Across 26 patients,...
Diagnostics platform growth: Co-Diagnostics advances point-of-care multiplex respiratory test
Co-Diagnostics submitted a 510(k) premarket notification to the FDA for its Co-Dx PCR Flu A/B, and RSV upper respiratory multiplex test, built for self- or clinician-collected nasal swabs. The...
Cell and gene therapy: BioMarin discontinues ENPP1 deficiency program after mixed Phase 3
BioMarin discontinued development of BMN401, its enzyme replacement therapy for ENPP1 deficiency, after mixed Phase 3 results that included missing one of two co-primary endpoints. The company...
Cancer early detection regulatory path
Grail said it is preparing for a likely FDA advisory committee meeting after the company submitted its premarket approval application for Galleri, its blood-based multi-cancer early detection...
FDA oncology designations accelerate development
The FDA handed out fast track and priority review designations across multiple oncology programs in July 2026, signaling continued regulatory momentum for new cancer mechanisms. The agency granted...
Melanoma approval closes Replimune’s accelerated approval saga
The FDA approved Replimune’s intratumoral oncolytic virus therapy for advanced melanoma after a sequence of prior rejections, granting accelerated approval for Tudriqev (formerly RP1). The...
Pulmonary fibrosis and cancer biotech pipeline gets new regulatory attention via expedited pathways
The FDA outlined a pilot approach to expedite review of new drugs as the agency focuses on narrowing developmental timelines and improving U.S. competitiveness. The program is described as an...
Rare disease failure reshapes BioMarin’s pipeline after ENPP1 deficiency exit
BioMarin ended development of BMN 401 in all indications after the biotech reported mixed Phase 3 results and ultimately stopped the program across the board. The company previously described the...
Oncology checkpoint-era science: tau mechanism links mitochondria dysfunction to neurodegeneration
Researchers tied Alzheimer’s-associated tau to a specific mitochondrial failure pathway, offering a more direct mechanistic target for tauopathy drug discovery. A Stanford study described how...
Alzheimer’s biomarker expansion across populations
A study evaluated plasma pTau217 performance in genetically admixed South American populations, aiming to expand biomarker evidence beyond populations traditionally represented in Alzheimer’s...
Biotech capital markets: major IPO fundraising for new biologic franchises
Attovia priced an upsized IPO to raise $298 million, with net proceeds expected to fund two large Phase 2 trials starting in early 2027. The company sold 17 million shares at $17 each, above an...
Biotech funding and workforce growth for transplant immunosuppression
LifeMine raised $263 million across two venture rounds to advance a potentially safer, more convenient immunosuppressant for transplant rejection, as the biotech aims to address clinical limits of...
Antimicrobial resistance policy and U.S. biotech leadership
A bipartisan Senate Finance Health Subcommittee hearing focused on linking antimicrobial resistance strategy with efforts to preserve U.S. biotech leadership. Lawmakers discussed the scale of AMR...